Skip to main
DFTX

DFTX Stock Forecast & Price Target

DFTX Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Definium Therapeutics is currently rated as a Buy due to four key factors. Firstly, its candidate DT120 ODT has a high probability of success in GAD, with Phase 3 data expected in early 2026. Second, GAD presents a large market opportunity for DT120, with potential for multi-billion dollar revenues. Third, recent data for DT120 in MDD showed impressive durability, setting it apart from other treatments. Finally, while DFTX has a higher market cap compared to other psychedelic companies, the space as a whole is undervalued, and DFTX is poised to be one of the leaders in this market. The company's DCF analysis gives a target price of $60, using a 10% discount rate and 0% terminal growth rate. The current offering has resulted in a slight decrease in the price target to $58, but the model still assumes a 65% probability of approval for MDD and 55% for GAD, which are reasonable given the positive data from the trials. DT120's profile, with less frequent dosing and strong efficacy, is expected to drive significant demand in the anxiety market, which has a high unmet need. Additionally, the company has other pipeline programs, such as DT402 for autism spectrum disorder

Bears say

Definium Therapeutics is facing significant risks in developing its products for neurological and psychiatric disorders, as trials can fail for various reasons and the safety and efficacy of its LSD D-tartrate orally disintegrating tablet/ODT, DT120, is yet to be fully established. Additionally, the company's approach may not be successful in producing the intended results, and regulatory bodies may not approve its products. There are also challenges related to achieving blinding in clinical trials for psychedelic products and potential difficulties in defending their intellectual property. Moreover, negative market perception and potential reimbursement-related challenges may hinder the company's success.

DFTX has been analyzed by 12 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Definium Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Definium Therapeutics Inc (DFTX) Forecast

Analysts have given DFTX a Buy based on their latest research and market trends.

According to 12 analysts, DFTX has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $51.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $51.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Definium Therapeutics Inc (DFTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.